Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCG Relapsed ALL 2017 Study
NCT04224571Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2018
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, bortezomib in acute lymphoblastic leukemia (ALL), sponsored by The Chinese University of Hong Kong. Started Sep 2018; status: completed.
02
Drugs
rituximabbortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04224571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224571.